Condition: Normal singleton pregnancy between 24 and 36 weeks gestation
Subject Age: 18 to 49 years
Subject Gender: Female
Enrollment Status: Pre-Enrolling (July 2020)
About the research study:
The study project will evaluate the efficacy and safety of a vaccine given to pregnant women designed to minimize or eliminate RSV symptoms in their newborns. This study is available at our Missoula, Kalispell, Great Falls, Helena, Butte, and Grand Junction locations.
Who can participate?
Subjects will be pregnant females from 18 to 49 years of age with a normal pregnancy between 24 and 36 weeks gestation.
What happens during the study?
Moms will receive a single vaccine during their pregnancy and have two blood draws - one before the vaccine and one at baby's birth. Infants will be monitored for any signs of respiratory illness during their first two years of life.
How long is the study?
Moms will participate until 6 months after delivery. Infants will be followed from birth until their 2nd birthday.